Endocrine sequelae and metabolic syndrome in adult long-term survivors of childhood acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 367-371

  Blijdorp, Karin ^a,b   van Waas, Marjolein ^a   van der Lely, Aart Jan ^b   Pieters, Rob ^a   van den Heuvel Eibrink, Marry ^a   Neggers, Sebastian ^a,b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Chemotherapy; Childhood cancer; Endocrine sequelae; Metabolic syndrome; Stem cell transplantation

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; INHIBIN B; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; ORAL CONTRACEPTIVE AGENT; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; FEMALE; FOLLOW UP; HUMAN; HYPOPHYSIS DISEASE; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; BLOOD PRESSURE; BONE DENSITY; CHILD; DYSLIPIDEMIAS; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; INSULIN RESISTANCE; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLIC SYNDROME X; SURVIVORS;

EID: 84875380837     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.12.008     Document Type: Article

References (35)

1. Chemaitilly W., Boulad F., Oeffinger K.C., Sklar C.A. Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study. Bone Marrow Transplant 2009, 44:339-343.
2. Neville K.A., Cohn R.J., Steinbeck K.S., et al. Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab 2006, 91:4401-4407.
3. Oudin C., Simeoni M.C., Sirvent N., et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 2011, 117:4442-4448.
4. Watson M., Wheatley K., Harrison G.A., et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999, 86:1231-1239.
5. van Casteren N.J., van der Linden G.H., Hakvoort-Cammel F.G., et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer 2009, 52:108-112.
6. Leung W., Hudson M.M., Strickland D.K., et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 2000, 18:3273-3279.
7. Liesner R.J., Leiper A.D., Hann I.M., Chessells J.M. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994, 12:916-924.
8. Le Meignen M., Auquier P., Barlogis V., et al. Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities. Blood 2011, 118:1481-1489.
9. Felicetti F., Manicone R., Corrias A., et al. Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: a retrospective study from a single institution. J Cancer Res Clin Oncol 2011, 137:1343-1348.
10. Brennan B.M., Shalet S.M. Endocrine late effects after bone marrow transplant. Br J Haematol 2002, 118:58-66.
11. Ogilvy-Stuart A.L., Clark D.J., Wallace W.H., et al. Endocrine deficit after fractionated total body irradiation. Arch Dis Child 1992, 67:1107-1110.
12. Shalet S.M., Brennan B.M. Growth and growth hormone status after a bone marrow transplant. Horm Res 2002, 58(Suppl 1):86-90.
13. Creutzig U., Reinhardt D. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - a European view. Br J Haematol 2002, 118:365-377.
14. Molgaard-Hansen L., Glosli H., Jahnukainen K., et al. Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study. Pediatr Blood Cancer 2011, 57:1222-1229.
15. Mulrooney D.A., Dover D.C., Li S., et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer 2008, 112:2071-2079.
16. Leahey A.M., Teunissen H., Friedman D.L., et al. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol 1999, 32:163-169.
17. Wendel-Vos G.C., Schuit A.J., Saris W.H., Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 2003, 56:1163-1169.
18. Khosla T., Lowe C.R. Indices of obesity derived from body weight and height. Br J Prev Soc Med 1967, 21:122-128.
19. WHO. Waist circumference and waist-hip ratio: report of a WHO Expert Consultation. Geneva, 8-11 December 2008, 2008.
20. Fredriks A.M., van Buuren S., Burgmeijer R.J., et al. Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 2000, 47:316-323.
21. Blokstra A, Smit HA, Mesquita HBBd et al. Monitoring van Risicofactoren en Gezondheid in Nederland (MORGEN-project), 1993-1997. Leefstijl-en risicofactoren: prevalenties en trends; 1997. Available from: [accessed 03.08.09]. http://www.rivm.nl/bibliotheek/rapporten/263200008.pdf.
22. Expert Panel on Detection E Treatment of high blood cholesterol in A. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III). JAMA 2001, 285:2486-2497.
23. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
24. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med 2007, 24:430-435.
25. van der Sluis I.M., de Ridder M.A., Boot A.M., et al. Reference data for bone density and body composition measured with dual energy X-ray absorptiometry in white children and young adults. Arch Dis Child 2002, 87:341-347. discussion 341-347.
26. Elmlinger M.W., Kuhnel W., Weber M.M., Ranke M.B. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004, 42:654-664.
27. de Vet A., Laven J.S., de Jong F.H., et al. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002, 77:357-362.
28. Kevenaar M.E., Meerasahib M.F., Kramer P., et al. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006, 147:3228-3234.
29. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
30. Driessen E.M., van der Velden V.H., Catsman-Berrevoets C.E., et al. Long-term survival after significant treatment reduction in a patient with CBF-AML. Pediatr Blood Cancer 2011, 56:325-326.
31. van der Does-van deb Berg A., Hhlen K., Colly L.P., Vossen J.M. Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine arabinoside, 6-thioguanine, and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG). Pediatr Hematol Oncol 1988, 5:93-102.
32. Slats A.M., Egeler R.M., van der Does-van deb Berg A., et al. Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005, 19:537-544.
33. van der Velden V.H., van der Sluijs-Geling A., Gibson B.E., et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010, 24:1599-1606.
34. Growth Hormone Research S Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000, 85:3990-3993.
35. van Waas M., Neggers S.J., Te Winkel M.L., et al. Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma. Ann Oncol 2011.